TKNO · Alpha Teknova, Inc.
$5.42
+0.10 (+1.88%)
At close · Jul 17
Market Cap
$290.59M
Shares
53,614,028
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$5.42
Open$5.23
Day$5.23–5.64
52W$1.91–6.68
Avg vol 30d205K
Short int1.3M · 2.3% float · 3.9d
Short vol55%
Last earningsMay 6, 2026
DataJun 2021–Jul 2026
Filing10-Q · May 7
Up next
Next earnings call
Aug 5, 2026
Est · unconfirmed
· in 2 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 7, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 18.8 · elevated
Equity put/call 0.73
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+35%
above
Price vs 50-day avg
+14%
above
RSI (14)
56
neutral
MACD trend
Negative
52-week position
74%
mid-range
Momentum
relative strength
1-month return
+9%
trailing
6-month return
+63%
trailing
YTD return
+43%
this year
Relative strength
+55%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $5 › 200d $4 — 50d above 200d
Institutional flow
Accumulating
3 of 77 funds reported for Jun 30 · net +83 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
2.33% of float · ▲ +27.8% MoM · 3.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
77 holders — near 3-yr high, broad support
Squeeze score
73
high risk · 0–100
Fundamentals
Revenue growth
+7%
Y/Y
Gross margin
33%
expanding
EPS growth
+44%
Y/Y
Free cash flow
$-9.8M
Balance sheet
$7.2M
net debt
Quant / Vol
risk profile
Volatility
81%
annualized · 1-yr
Max drawdown
−69%
past year
ATR
7.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed May 6, 2026
Free Cash Outflow
· 2026
Non-GAAP
Initiated
up to $10M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+35%
Bullish
Price vs 50-day avg
+14%
Bullish
RSI (14)
56
Neutral
MACD trend
Negative
Bearish
52-week position
74%
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $5 › 200d $4 — 50d above 200d
Institutional flow
Accumulating
3 of 77 funds reported for Jun 30 · net +83 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
2.33% of float · ▲ +27.8% MoM · 3.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
77 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $2
Now $5 · 74%
52-wk high $7
vs 200-day avg +35%
vs 50-day avg +14%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Free Cash Outflow non-GAAP | $3.6M | the first quarter 2026 | — |
| Adjusted EBITDA non-GAAP | -$6.7M | the full year 2025 | — |
| Clinical Solutions customers | 25% | the full year 2025 | — |
| Free Cash Flow non-GAAP | -$9.8M | the full year 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TKNO
this stock
Alpha Teknova, Inc.
|
$290.59M | +42.6% | +2.9% | — | 2.3% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$54.77B | +10.0% | — | — | 0.2% |
|
GALDY
Galderma Group AG/ADR
|
$50.12B | +3.1% | — | — | 0.0% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$45.13B | — | — | — | 0.0% |
|
HLN
Haleon plc
|
$44.48B | -0.1% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TKNO | +1.1% | +9.5% | +63.3% | -4.6% | +42.6% |
| SPY | -1.5% | +0.3% | +7.8% | -0.5% | +9.0% |
| vs SPY | +2.7% | +9.2% | +55.4% | -4.1% | +33.6% |